{"product_id":"ipsc-marketing-mix","title":"(IPSC) Century Therapeutics, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Century Therapeutics, Inc. 4P's Marketing Mix Analysis explains the company’s product offering (cellular therapies), its intended clinical\/commercial use, pricing considerations, channels, and promotional tactics in a concise, actionable format. This page includes a real preview\/sample of the analysis so you can evaluate style and content—purchase the full version to unlock the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCNTY-101 CD19 CAR-iNK\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCNTY-101 is Century Therapeutics, Inc.'s lead clinical program and most advanced asset: an allogeneic iPSC-derived CAR-iNK therapy aimed at CD19 in relapsed or refractory B-cell lymphoma. As the flagship Product in the lineup, it sits at the center of the company’s product strategy and pipeline value. Its market role is clear: a cell therapy designed for hard-to-treat blood cancers where current options often fail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCNTY-103 CD133+EGFR CAR-iNK\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCNTY-103 is Century Therapeutics, Inc.’s allogeneic CAR-iNK candidate for recurrent glioblastoma, aimed at CD133 and EGFR, two markers linked to tumor growth and recurrence. The product pushes Century Therapeutics, Inc. beyond cell therapy for blood cancers into solid tumors, a far larger market where glioblastoma still has a median survival near 15 months and a 5-year survival below 5%. This gives the program clear product differentiation and high unmet-need pull.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCNTY-102 CD19+CD79b CAR-iT\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCNTY-102 is Century Therapeutics, Inc.'s CAR-iT candidate in development for relapsed or refractory B-cell lymphoma and other B-cell cancers. It targets both CD19 and CD79b, two validated B-cell antigens, to help address antigen escape. In the 4P mix, this is a high-value Product aimed at patients with strong unmet need in a crowded hematology market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCNTY-104 AML multi-specific CAR-iT or CAR-iNK\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCNTY-104 is Century Therapeutics, Inc.'s multi-specific cell therapy for acute myeloid leukemia, built as either CAR-iT or CAR-iNK. It widens the pipeline into myeloid malignancies, a hard-to-treat area where U.S. AML still causes about 20,800 new cases a year and about 11,220 deaths.\u003c\/p\u003e\n\u003cp\u003eFor the 4P lens, the product targets a high-unmet-need niche with a broader antigen strategy than a single-target CAR. That matters because AML has a 5-year relative survival near 32.9%, so even small gains can drive strong clinical and commercial value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget: acute myeloid leukemia\u003c\/li\u003e\n\u003cli\u003eFormat: CAR-iT or CAR-iNK\u003c\/li\u003e\n\u003cli\u003eRole: expands myeloid pipeline\u003c\/li\u003e\n\u003cli\u003eNeed: high unmet, low survival\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCNTY-106 multiple myeloma program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCNTY-106 is Century Therapeutics, Inc. multi-specific cell therapy for multiple myeloma, adding a plasma-cell cancer target to the pipeline. Multiple myeloma drives about 35,000 new U.S. cases a year, so this program expands the addressable market if the therapy shows durable response and manageable safety in clinic.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMulti-specific cell therapy candidate\u003c\/li\u003e\n\u003cli\u003eTargets multiple myeloma\u003c\/li\u003e\n\u003cli\u003eAdds plasma-cell cancer coverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentury Therapeutics Builds a Broad iPSC Cell Therapy Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCentury Therapeutics, Inc.'s Product mix is built around six iPSC-derived cell therapy programs: CNTY-101, CNTY-102, CNTY-103, CNTY-104, and CNTY-106. The lead asset is CNTY-101 for relapsed or refractory B-cell lymphoma, while the rest widen coverage into glioblastoma, AML, and multiple myeloma. This gives Century Therapeutics, Inc. a focused, high-unmet-need pipeline across blood and solid tumors.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eFocus\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCNTY-101\u003c\/td\u003e\n\u003ctd\u003eB-cell lymphoma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCNTY-103\u003c\/td\u003e\n\u003ctd\u003eGlioblastoma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCNTY-106\u003c\/td\u003e\n\u003ctd\u003eMultiple myeloma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a concise, company-specific 4P’s analysis of Century Therapeutics, Inc.’s Product, Price, Place, and Promotion strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eSummarizes Century Therapeutics’ 4Ps in a clear, at-a-glance format that speeds alignment and simplifies strategic discussion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise bibliography linking Century Therapeutics claims to industry reports, clinical data, SEC filings, and trusted benchmarks for fast, defensible due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhiladelphia, Pennsylvania HQ\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCentury Therapeutics, Inc. is headquartered in Philadelphia, Pennsylvania, and was established in 2018. The city serves as the center for its corporate and research work, keeping leadership and R\u0026amp;D close to one site.\u003c\/p\u003e\n\u003cp\u003eThis U.S. base supports the company’s cell-therapy development and day-to-day decision-making, which is important for speed in a science-driven business.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial site model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCentury Therapeutics, Inc. uses a clinical trial site model, so its therapies reach patients through oncology centers and trial sites, not retail shelves. As a clinical-stage biotech, the channel is built around investigator-led studies that test safety and efficacy before any commercial launch. This keeps the go-to-market path tightly tied to trial enrollment and site access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllogeneic iPSC manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCentury Therapeutics, Inc. uses an allogeneic iPSC platform, so cell therapy can be made in centralized batches instead of one-by-one for each patient. That makes shipment to treatment sites the operating model, not on-site manufacturing, and it can improve scale and consistency. In 2025-2026, the key advantage is speed and supply control versus autologous therapies, which must be made for each patient.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHospital administration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCentury Therapeutics, Inc. keeps hospital administration tightly tied to the point of care because cell therapies must be infused in hospitals or specialized cancer centers. That model fits the way FDA-cleared cell therapies are handled: certified sites manage cryogenic storage, patient monitoring, and rapid adverse-event response. It also cuts last-mile distribution risk and keeps product flow close to the treating team.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdministered in hospitals or cancer centers\u003c\/li\u003e\n\u003cli\u003ePoint-of-care delivery reduces handling risk\u003c\/li\u003e\n\u003cli\u003eCertified sites support safety monitoring\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNo retail or online channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCentury Therapeutics uses 0 retail stores, 0 pharmacies, and 0 e-commerce channels. Its products are investigational biologics, so access stays inside regulated clinical trial sites now and, if approved later, would shift to specialty oncology distribution. That makes the place strategy fully B2B and clinician-led, not consumer-led.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003e0 direct consumer channels\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eClinical-site access only\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eFuture specialty oncology route\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentury Therapeutics: Clinical-Only Access Through Trial Sites and Cancer Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCentury Therapeutics, Inc. keeps Place fully clinical and B2B: headquarters in Philadelphia, Pennsylvania, and patient access through oncology trial sites and specialized hospitals, not retail. Its centralized allogeneic iPSC model supports shipment to certified treatment centers, which reduces last-mile handling and fits 2025-2026 cell-therapy logistics.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace factor\u003c\/th\u003e\n\u003cth\u003eCurrent setup\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHQ\u003c\/td\u003e\n\u003ctd\u003ePhiladelphia, Pennsylvania\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChannel\u003c\/td\u003e\n\u003ctd\u003eClinical trial sites only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail channels\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdmin sites\u003c\/td\u003e\n\u003ctd\u003eHospitals, cancer centers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eCentury Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Century Therapeutics 4P's Marketing Mix document you’ll receive instantly after purchase—no surprises. It’s the full, editable analysis covering Product, Price, Place, and Promotion tailored to Century Therapeutics, ready for immediate use in strategy or reporting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestor relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCentury Therapeutics' promotion is aimed at investors and analysts, with earnings materials, presentations, and SEC filings doing most of the work. As a pre-commercial biotech, it has no product revenue, so investor relations is key for sharing pipeline updates and cash-runway detail. This is standard for firms still funding research instead of selling approved products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePress releases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCentury Therapeutics uses press releases to announce pipeline, trial, and financing updates, keeping investors aligned with key development milestones. In 2025, public biotech firms still relied on this channel because each trial readout or capital raise can move valuation fast. For Century Therapeutics, these releases are a core promotion tool that supports transparency and market awareness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific congresses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScientific congresses let Century Therapeutics, Inc. present preclinical and clinical data to researchers and physicians. Meetings like ASCO, with more than 40,000 attendees, and ASH, with over 30,000, give the company a strong stage to build credibility and peer review. For a biotech with no approved product revenue, that visibility can support trust and partnering interest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical trial disclosures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCentury Therapeutics promotes clinical trial disclosures through public registries and study updates, so investigators and patients can track progress in real time. In 2025, its disclosed pipeline still centered on early-stage allogeneic cell therapy programs, including CTX112 and CTX131, which helped keep trial visibility high. This also supports transparency on development milestones and patient access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublic registries raise trial awareness\u003c\/li\u003e\n\u003cli\u003eUpdates improve patient and investigator reach\u003c\/li\u003e\n\u003cli\u003eDisclosures build trust through transparency\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eWebsite and corporate pipeline updates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCentury Therapeutics, Inc. uses its website and pipeline pages to show its cell therapy candidates and target indications in one place. That keeps the product story consistent for investors, partners, and analysts. It matters because Century Therapeutics, Inc. does not rely on consumer advertising, so the site is a core channel.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClear candidate and indication map\u003c\/li\u003e\n\u003cli\u003eSingle, consistent pipeline story\u003c\/li\u003e\n\u003cli\u003ePrimary channel without consumer ads\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn its 2025 reporting, Century Therapeutics, Inc. still had no product sales, so pipeline updates are a key signal of progress.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentury Therapeutics Builds Trust With Pipeline-First Updates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCentury Therapeutics, Inc. promotes mainly through investor materials, SEC filings, press releases, and scientific congresses because it had no product sales in 2025. Its CTX112 and CTX131 updates keep analysts, investigators, and partners aligned on pipeline progress and cash use.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eIR, press, congresses\u003c\/td\u003e\n\u003ctd\u003eBuild trust and visibility\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo approved commercial product\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCentury Therapeutics, Inc. had no approved commercial therapy as of July 2026, so there is no list price to report. Pricing is not yet applicable because the Company has no marketed product and no sales from an approved therapy. This keeps the price element of the 4P's mix at zero until regulatory approval and launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo public list price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCentury Therapeutics, Inc. has not disclosed a public list price for CNTY-101 or any other pipeline asset, so the current price is effectively $0 in the market. As a clinical-stage biotech, the company has no retail launch pricing yet, and any price would only come after FDA approval and commercial launch. That means pricing power is still untested, with value tied more to trial data than to a posted price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrial supply is sponsor-funded\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCentury Therapeutics, Inc. trial supply is sponsor-funded, so patients usually pay $0 for the investigational therapy. In clinical development, access comes through site enrollment and protocol rules, not a market sale. That keeps pricing out of the patient channel until any approved product reaches a paid market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHospital and payer negotiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIf Century Therapeutics, Inc. wins approval, hospital and payer negotiation will set the net price. In U.S. cell therapy, specialty medical benefit coverage is common, and public list prices for CAR-T drugs have ranged from about $373,000 to $487,000 per treatment.\u003c\/p\u003e\n\u003cp\u003eThe final price will hinge on prior auth, outcomes data, and hospital margin pressure. A strong value case can lift coverage; weak evidence can force discounts or risk-based deals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNegotiated with hospitals and payers\u003c\/li\u003e\n\u003cli\u003eSpecialty medical channel reimbursement\u003c\/li\u003e\n\u003cli\u003eCoverage drives net realized price\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty oncology pricing model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCentury Therapeutics' cancer cell-therapy pipeline sits in premium specialty biologics, where U.S. CAR-T list prices often range from about $373,000 to $475,000 per treatment. That pricing fits the high unmet need and complex manufacturing, including patient-specific cell processing and cold-chain delivery. In this class, price is tied more to clinical value and production difficulty than to volume.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePremium, hospital-based oncology use\u003c\/li\u003e\n\u003cli\u003eComplex manufacturing lifts price\u003c\/li\u003e\n\u003cli\u003eHigh unmet need supports premium pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentury Therapeutics Price: $0 Now, CAR-T Pricing Could Be $373K-$487K\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCentury Therapeutics, Inc. had no approved product as of July 2026, so its Price stays at $0 for now. In trials, patients usually pay $0 because sponsor-funded supply is used. If approved, pricing will be set by hospital and payer talks, with CAR-T list prices often around $373,000 to $487,000 per treatment.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePrice\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent list price\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial patient cost\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLikely future class range\u003c\/td\u003e\n\u003ctd\u003e$373,000-$487,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234567758089,"sku":"ipsc-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/ipsc-marketing-mix.webp?v=1785722266","url":"https:\/\/dcfanalyst.com\/products\/ipsc-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}